secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evommune, Inc. (EVMN)
CIK:        0002044725
Form:       8-K
Filed at:   2026-10-01T12:01:58+00:00
Accession:  0001193125-26-409865
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Evommune's EVO301 hits Phase 2a primary endpoint in atopic dermatitis: 55% EASI reduction vs 22% placebo
--------------------------------------------------------------------------------

- Phase 2a trial (n=70; 48 active, 22 placebo) of IV EVO301 5mg/kg at Baseline and Week 4 met its primary endpoint: 55% LS mean EASI reduction at Week 12 vs 22% on placebo (p<0.01).
- EASI-50 at Week 12 was 63% for EVO301 vs 23% placebo; EASI-75 was 29% vs 9%; separation appeared by Week 4 (41% vs 18%) and held through Week 8 (50% vs 16%).
- Safety: no treatment-related serious or severe adverse events, no discontinuations, no conjunctivitis; treatment-related AEs in 10.4% of EVO301 patients vs 13.6% on placebo.
- Biomarkers: ~75% reduction in CCL-17 (TARC) in patients with high baseline TARC, with reductions also in CCL-22, IL-22 and Th1/Th17/Th22 pathway markers.
- Subcutaneous Phase 2b dose-ranging trial on track to begin mid-2027; PK profile supports Q4-week dosing with potential every-8-to-12-week maintenance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2044725/000119312526409865/0001193125-26-409865-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2044725/000119312526409865/evmn-20261001.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-409865

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer